Maravai LifeSciences (MRVI) Tops Q4 EPS by 7c; Guides Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Maravai LifeScience Holdings Inc. (MRVI) PT Lowered to $45 at Stifel
February 24, 2022 7:14 AM ESTStifel analyst Daniel Arias lowered the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $45.00 (from $56.00) while maintaining a Buy rating.
The analyst commented, "MRVI posted a solid top- and bottom-line beat driven by strength in CleanCap. Along with earnings, management provided... More
